Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers

Table 7

Parametric point estimates for C_max after dose adjustment.

Cmax
Comparison		PE (%)	90% CI (%)		CVANOVA (%)	Power (%)
INTRANASAL	INTRAVENOUS	37.22	30.15	45.94	44.50	54.13
INTRANASAL	TRANSMUCOSAL	105.97	94.47	118.88	23.50	94.00
TRANSMUCOSAL	INTRAVENOUS	35.12	28.06	43.96	47.70	49.72
TRANSMUCOSAL	INTRAVENOUS	8.78	7.02	10.99	45.60	49.72
INTRANASAL	TRANSMUCOSAL	463.88	424.64	506.73	17.90	94.00

Dose adjusted to 50 μg fentanyl. dose adjusted to 47 μg fentanyl. AUC_0-tlast: area under the plasma concentration versus time curve from dosing time to the last measurement time point with concentration value above the lower limit of quantitation; C_max: maximum concentration in plasma; PE: parametric point estimate; CI: confidence interval; CV%: coefficient of variation.